Vertex Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Vertex Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 1.4%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento anual de 19.1%. Los ingresos han ido creciendo a una tasa media de 17.6% al año.
Información clave
1.4%
Tasa de crecimiento de los beneficios
1.5%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | 17.6% |
| Rentabilidad financiera | -3.1% |
| Margen neto | -4.5% |
| Última actualización de beneficios | 30 Sep 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Nov 05Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Oct 18Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
Oct 10Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Sep 15Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Sep 05Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Aug 02Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?
Jul 11
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Jul 09If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jun 20Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03Desglose de ingresos y gastos
Cómo gana y gasta dinero Vertex Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 24 | 10,626 | -480 | 1,456 | 0 |
| 30 Jun 24 | 10,337 | -490 | 1,348 | 0 |
| 31 Mar 24 | 10,185 | 4,019 | 1,238 | 0 |
| 31 Dec 23 | 9,869 | 3,620 | 1,137 | 0 |
| 30 Sep 23 | 9,654 | 3,470 | 1,035 | 0 |
| 30 Jun 23 | 9,505 | 3,365 | 1,018 | 0 |
| 31 Mar 23 | 9,208 | 3,260 | 971 | 0 |
| 31 Dec 22 | 8,931 | 3,322 | 945 | 0 |
| 30 Sep 22 | 8,701 | 3,273 | 933 | 0 |
| 30 Jun 22 | 8,350 | 3,195 | 884 | 0 |
| 31 Mar 22 | 7,948 | 2,451 | 863 | 0 |
| 31 Dec 21 | 7,574 | 2,342 | 840 | 0 |
| 30 Sep 21 | 7,130 | 2,176 | 797 | 0 |
| 30 Jun 21 | 6,684 | 1,992 | 783 | 0 |
| 31 Mar 21 | 6,415 | 2,762 | 780 | 0 |
| 31 Dec 20 | 6,206 | 2,712 | 771 | 0 |
| 30 Sep 20 | 5,991 | 2,691 | 754 | 0 |
| 30 Jun 20 | 5,403 | 2,081 | 729 | 0 |
| 31 Mar 20 | 4,819 | 1,511 | 694 | 0 |
| 31 Dec 19 | 4,163 | 1,177 | 659 | 0 |
| 30 Sep 19 | 3,620 | 2,144 | 616 | 0 |
| 30 Jun 19 | 3,454 | 2,215 | 594 | 0 |
| 31 Mar 19 | 3,265 | 2,155 | 575 | 0 |
| 31 Dec 18 | 3,048 | 2,096 | 558 | 0 |
| 30 Sep 18 | 2,829 | 647 | 539 | 0 |
| 30 Jun 18 | 2,623 | 415 | 523 | 0 |
| 31 Mar 18 | 2,415 | 226 | 513 | 0 |
| 31 Dec 17 | 2,489 | 263 | 496 | 0 |
| 30 Sep 17 | 2,296 | 196 | 471 | 0 |
| 30 Jun 17 | 2,131 | 259 | 457 | 0 |
| 31 Mar 17 | 2,019 | 177 | 441 | 0 |
| 31 Dec 16 | 1,702 | -112 | 433 | 0 |
| 30 Sep 16 | 1,661 | -219 | 419 | 0 |
| 30 Jun 16 | 1,557 | -275 | 413 | 0 |
| 31 Mar 16 | 1,292 | -399 | 396 | 0 |
| 31 Dec 15 | 1,032 | -556 | 377 | 0 |
| 30 Sep 15 | 759 | -659 | 359 | 0 |
| 30 Jun 15 | 628 | -734 | 334 | 0 |
| 31 Mar 15 | 600 | -704 | 317 | 0 |
| 31 Dec 14 | 580 | -738 | 305 | 0 |
| 30 Sep 14 | 787 | -582 | 300 | 0 |
| 30 Jun 14 | 830 | -530 | 308 | 0 |
| 31 Mar 14 | 1,002 | -428 | 338 | 0 |
| 31 Dec 13 | 1,212 | -504 | 356 | 0 |
Ingresos de calidad: VRTX actualmente no es rentable.
Margen de beneficios creciente: VRTX actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: VRTX no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 1.4% por año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de VRTX en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: VRTX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (16.6%).
Rentabilidad financiera
Alta ROE: VRTX tiene una rentabilidad financiera negativa (-3.07%), ya que actualmente no es rentable.